Irving, Texas — According to state and local economic development sources MedPace plans to invest $1,325,000.00 to build out 45,851 square feet of new space in Irving. The company plans to occupy the new space at 2100-2120 W. Walnut Hill in Irving, on or about April 1, 2020. According to the company website Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 2,700 people across 36 countries.

To learn more about MedPace, visit http://www.medpace.com/

Company Contact:
August Troendle, Chief Executive Officer
a.troendle@medpace.com
https://www.linkedin.com/in/august-troendle-173330180/
513-579-9911

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved